SARS-CoV-2 Infection Prevented and Treated in Human Lung Tissue Model
Excerpt from the Article:
Given the steady numbers of new COVID-19 cases, the appearance of new variants, and the considerable time that vaccinations will take to reach target levels needed for herd immunity, the development of treatments and useful therapeutics remains a top priority. In particular, treatments and preventive approaches that can be widely and rapidly implemented are urgently needed to curb the risk for COVID-19 related hospitalization and death in multiple settings including nursing homes and long-term care facilities.
Now, scientists at UNC have found that the orally administered experimental drug EIDD-2801 (now known as molnupiravir or MK-4482) halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue. Separate Phase II and III clinical trials are ongoing to evaluate molnupiravir safety in humans and its effect on viral shedding in COVID-19 patients, and the first results could be released as early as March.
Click the button below to read the entire Article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?